William Blair Reiterates Buy Rating for Gilead Sciences, Inc. (GILD)
Other research analysts have also issued reports about the stock. TheStreet upgraded shares of Gilead Sciences from a c+ rating to a b- rating in a research note on Thursday, September 7th. Zacks Investment Research upgraded shares of Gilead Sciences from a hold rating to a buy rating and set a $79.00 target price on the stock in a research note on Monday, July 17th. Vetr lowered shares of Gilead Sciences from a strong-buy rating to a buy rating and set a $75.40 target price on the stock. in a research note on Wednesday, June 21st. Jefferies Group LLC reiterated a buy rating and issued a $82.00 target price on shares of Gilead Sciences in a research note on Tuesday, July 4th. Finally, Deutsche Bank AG started coverage on shares of Gilead Sciences in a research note on Friday, June 23rd. They issued a buy rating and a $79.00 target price on the stock. One research analyst has rated the stock with a sell rating, twelve have given a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has a consensus rating of Buy and a consensus price target of $85.64.
Gilead Sciences (GILD) traded down 0.86% during trading on Thursday, hitting $80.51. 2,721,907 shares of the company traded hands. Gilead Sciences has a one year low of $63.76 and a one year high of $86.27. The firm has a 50 day moving average of $82.63 and a 200 day moving average of $72.65. The firm has a market cap of $105.14 billion, a P/E ratio of 8.74 and a beta of 1.14.
Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.11 by $0.45. Gilead Sciences had a net margin of 42.90% and a return on equity of 66.07%. The business had revenue of $7.14 billion for the quarter, compared to analyst estimates of $6.35 billion. During the same period last year, the business posted $3.08 EPS. Gilead Sciences’s revenue was down 8.2% compared to the same quarter last year. On average, analysts expect that Gilead Sciences will post $8.74 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION WARNING: “William Blair Reiterates Buy Rating for Gilead Sciences, Inc. (GILD)” was originally published by Watch List News and is the property of of Watch List News. If you are reading this news story on another publication, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this news story can be accessed at https://www.watchlistnews.com/william-blair-reiterates-buy-rating-for-gilead-sciences-inc-gild/1649700.html.
The company also recently disclosed a quarterly dividend, which was paid on Thursday, September 28th. Investors of record on Friday, September 15th were given a dividend of $0.52 per share. The ex-dividend date of this dividend was Thursday, September 14th. This represents a $2.08 annualized dividend and a yield of 2.56%. Gilead Sciences’s dividend payout ratio is 22.58%.
In related news, insider John C. Martin sold 73,333 shares of the company’s stock in a transaction dated Tuesday, August 1st. The shares were sold at an average price of $75.86, for a total transaction of $5,563,041.38. Following the completion of the sale, the insider now owns 3,199,969 shares of the company’s stock, valued at $242,749,648.34. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Robin L. Washington sold 51,820 shares of the company’s stock in a transaction dated Thursday, September 7th. The stock was sold at an average price of $85.00, for a total transaction of $4,404,700.00. Following the sale, the chief financial officer now directly owns 43,352 shares of the company’s stock, valued at approximately $3,684,920. The disclosure for this sale can be found here. Insiders have sold 446,819 shares of company stock valued at $36,338,919 in the last ninety days. 1.30% of the stock is currently owned by company insiders.
Several hedge funds have recently bought and sold shares of GILD. Sanders Capital LLC bought a new position in shares of Gilead Sciences in the third quarter worth about $427,585,000. Parnassus Investments CA lifted its holdings in shares of Gilead Sciences by 37.4% in the first quarter. Parnassus Investments CA now owns 16,726,150 shares of the biopharmaceutical company’s stock worth $1,110,228,000 after acquiring an additional 4,556,901 shares during the last quarter. Bank of New York Mellon Corp lifted its holdings in shares of Gilead Sciences by 9.8% in the first quarter. Bank of New York Mellon Corp now owns 30,570,798 shares of the biopharmaceutical company’s stock worth $2,076,368,000 after acquiring an additional 2,727,063 shares during the last quarter. Renaissance Technologies LLC lifted its holdings in shares of Gilead Sciences by 35.0% in the second quarter. Renaissance Technologies LLC now owns 10,407,848 shares of the biopharmaceutical company’s stock worth $736,667,000 after acquiring an additional 2,700,600 shares during the last quarter. Finally, Vanguard Group Inc. lifted its holdings in shares of Gilead Sciences by 2.4% in the second quarter. Vanguard Group Inc. now owns 92,841,960 shares of the biopharmaceutical company’s stock worth $6,571,355,000 after acquiring an additional 2,148,697 shares during the last quarter. 73.97% of the stock is owned by hedge funds and other institutional investors.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.